Final Medicare drug pricing rule scaled back, savings 96% below initial proposal

CMS issued a final rule to lower Medicare Part B drug prices, but it applies to only four companies and yields savings 96% less than originally proposed. The rule's narrowed scope suggests significant industry pushback or administrative constraints, reducing expected fiscal impact. This matters for pharmaceutical pricing dynamics and Medicare's cost trajectory.